Minerva Neurosciences (NERV) News
NASDAQ: NERVHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
NERV news summary
We found 3 recent headlines mentioning Minerva Neurosciences (NERV): 1 in the past week and 3 in the past 30 days, most often from GlobeNewswire, Nasdaq. NERV is making an outsized move today, down 5.66% at $2.00, which often coincides with company-specific news. Check the latest headlines below for the likely catalyst. The most recent story, "Minerva Neurosciences, Inc. Revises November 12, 2026 KOL Event Transcript to Clarify Regulatory Statements", was published by Nasdaq on Nov 16, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Minerva Neurosciences headlines
- Minerva Neurosciences, Inc. Revises November 12, 2026 KOL Event Transcript to Clarify Regulatory StatementsMinerva Neurosciences, Inc. has furnished a revised transcript of its November 12, 2026 key opinion leader event regarding roluperidone, its product candidate for treating negative symptoms in…Nasdaq
- Minerva Neurosciences Provides Third Quarter 2026 Financial Results and Business UpdatesConfirmatory Phase 3 trial of roluperidone (MIN-101C19) ongoing with topline efficacy data expected 2H 2027GlobeNewswire
- Minerva Neurosciences to Participate in 2026 Jefferies Global Healthcare Conference in LondonBURLINGTON, Mass., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central…GlobeNewswire